Search results for "drug evaluation"

showing 10 items of 188 documents

High-throughput screening with the Eimeria tenella CDC2-related kinase2/cyclin complex EtCRK2/EtCYC3a

2012

The poultry disease coccidiosis, caused by infection with Eimeria spp. apicomplexan parasites, is responsible for enormous economic losses to the global poultry industry. The rapid increase of resistance to therapeutic agents, as well as the expense of vaccination with live attenuated vaccines, requires the development of new effective treatments for coccidiosis. Because of their key regulatory function in the eukaryotic cell cycle, cyclin-dependent kinases (CDKs) are prominent drug targets. The Eimeria tenella CDC2-related kinase 2 (EtCRK2) is a validated drug target that can be activated in vitro by the CDK activator XlRINGO (Xenopus laevis rapid inducer of G2/M progression in oocytes). B…

In silicoPlasmodium falciparumAntiprotozoal AgentsDrug Evaluation PreclinicalProtozoan ProteinsMicrobiologyEimeriaMicrobiology03 medical and health sciences0302 clinical medicineCyclin-dependent kinaseCyclinsparasitic diseasesCDC2 Protein KinaseAnimalsEnzyme Inhibitors030304 developmental biologyCyclin0303 health sciencesCyclin-dependent kinase 1biologyKinaseComputational BiologyPlasmodium falciparumCell cyclebiology.organism_classificationVirologyStandard3. Good healthHigh-Throughput Screening Assays030220 oncology & carcinogenesisCell and Molecular Biology of Microbesbiology.proteinEimeria tenellaMicrobiology
researchProduct

A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma.

1989

Recent preclinical and clinical studies that have demonstrated antitumor activity of high-dose recombinant interleukin-2 (rIL-2), and animal models that demonstrated a synergistic effect of low-dose cyclophosphamide, led us to study rIL-2 (Cetus Corp., Emeryville, Calif) in a phase II clinical trial in combination with low-dose cyclophosphamide in 32 patients, 18 with malignant melanoma and 14 with renal cell carcinoma. rIL-2 was given once daily at 3 x 10(6) U/m2, as a 30-min infusion for 14 days in cycle I and for 2 x 5 days in cycles II and III respectively; if tolerated, the dose was increased to a maximum of 6 x 10(6) U m-2 day-1; the cycles, separated by 1 week treatment-free interval…

Interleukin 2AdultMaleCancer Researchmedicine.medical_specialtyPathologyCyclophosphamidemedicine.medical_treatmentImmunologyPhases of clinical researchGastroenterologyDrug Administration ScheduleRenal cell carcinomaInternal medicineAntineoplastic Combined Chemotherapy ProtocolsImmunology and AllergyMedicineHumansNeoplasm MetastasisCyclophosphamideMelanomaAgedChemotherapyKidneybusiness.industryMelanomaCarcinomaRemission InductionReceptors Interleukin-2Middle Agedmedicine.diseaseKidney NeoplasmsRecombinant ProteinsBlood Cell Countmedicine.anatomical_structurePhenotypeOncologyDrug EvaluationInterleukin-2FemaleBolus (digestion)businessmedicine.drugCancer immunology, immunotherapy : CII
researchProduct

Efficacy and safety of tafluprost 0.0015% and timolol maleate 0.5% fixed combination in patients with ocular hypertension or open-angle glaucoma.

2014

Lowering intraocular pressure (IOP) is at present the only therapeutic approach to the treatment of glaucoma proven to be successful. The choice of therapy must take into account efficacy, tolerability, safety, quality of life, adherence and cost. Monotherapy fails to achieve a satisfactory IOP reduction in 40 - 75% of glaucoma patients after2 years of therapy. So far, three prostaglandin/timolol maleate 0.5% fixed combinations (FCs) are available.This review provides a background on the tafluprost-timolol FC (TTFC, Santen Oy) and its individual compounds. It summarizes the data on efficacy and safety, including comparative data with prostaglandin/timolol FCs already available.Tafluprost is…

Intraocular pressuregenetic structuresOpen angle glaucomaDrug-Related Side Effects and Adverse ReactionsOcular hypertensionTimololGlaucomamedicineHumansPharmacology (medical)Antihypertensive AgentsPharmacologybusiness.industryProstaglandins FTafluprostGlaucomaGeneral Medicinemedicine.diseaseeye diseasesDrug CombinationsProstaglandin analogTolerabilityAnesthesiaTimololDrug Evaluationlipids (amino acids peptides and proteins)Ocular Hypertensionsense organsbusinessGlaucoma Open-Anglemedicine.drugExpert opinion on pharmacotherapy
researchProduct

Identification of avarol derivatives as potential antipsoriatic drugs using an in vitro model for keratinocyte growth and differentiation.

2006

Contains fulltext : 49512schalkwijk.pdf (Publisher’s version ) (Closed access) Avarol, a marine sesquiterpenoid hydroquinone, and 14 avarol derivatives have shown interesting anti-inflammatory properties in previous studies. In this study, avarol and derivatives were evaluated in high-throughput keratinocyte culture models using cytokeratin 10 and SKALP/Elafin expression as markers for respectively normal and psoriatic differentiation. Avarol and five of its derivatives (5, 10, 13, 14 and 15) were selected for further study. Only 10, 13, 14 and 15 were able to inhibit keratinocyte cell growth. Changes in expression levels of 22 genes were assessed by quantitative real time PCR (qPCR). From …

KeratinocytesDrug Evaluation PreclinicalAntineoplastic AgentsEnzyme-Linked Immunosorbent AssayIn Vitro TechniquesBiologyGeneral Biochemistry Genetics and Molecular BiologyDownregulation and upregulationTranslational research [ONCOL 3]DysideaGene expressionDithranolmedicineAnimalsHumansPsoriasisRNA MessengerGeneral Pharmacology Toxicology and PharmaceuticsCells CulturedCell ProliferationChronic inflammation and autoimmunity [UMCN 4.2]Messenger RNATumor Necrosis Factor-alphaCell growthInterleukin-8Membrane ProteinsCell DifferentiationGeneral MedicineMolecular biologyElafinPathogenesis and modulation of inflammation [N4i 1]medicine.anatomical_structureMechanism of actionCyclooxygenase 2KeratinsClinical Pharmacology and physiology [CTR 2]medicine.symptomKeratinocyteSesquiterpenesInfection and autoimmunity [NCMLS 1]Elafinmedicine.drug
researchProduct

Allopurinol Protective Effect of Renal Ischemia by Downregulating TNF-α, IL-1β, and IL-6 Response

2016

Allopurinol is a well-known antioxidant that protects tissue against ischemia and reperfusion injury, blocking purine catabolism, and possibly reducing TNF-α and other cytokines. It also plays a significant role in reducing the inflammatory processes by inhibiting chemotaxis and other inflammatory mediators. The objective of this study was to define the role of allopurinol regarding kidney ischemic injury particularly as to its effect on inflammatory molecules such as TNF-α, IL-1β, and IL-6 response. One hundred and twenty five rats were subjected to warm renal ischemia. Five more animals were included as sham. Animal survival and plasma levels of lipid peroxidation, myeloperoxidase, lactat…

Male0301 basic medicineAllopurinolDrug Evaluation PreclinicalIschemiaAllopurinolPharmacologyKidneyGout SuppressantsLipid peroxidation03 medical and health scienceschemistry.chemical_compound0302 clinical medicineLactate dehydrogenaseAnimalsMedicineRats WistarKidneybiologyRenal ischemiaInterleukin-6Tumor Necrosis Factor-alphabusiness.industryInterleukin-18Acute Kidney Injurymedicine.disease030104 developmental biologymedicine.anatomical_structurechemistryReperfusion Injury030220 oncology & carcinogenesisMyeloperoxidaseImmunologybiology.proteinSurgerybusinessReperfusion injurymedicine.drugJournal of Investigative Surgery
researchProduct

Melatonin protects rats from radiotherapy-induced small intestine toxicity

2017

Radiotherapy-induced gut toxicity is among the most prevalent dose-limiting toxicities following radiotherapy. Prevention of radiation enteropathy requires protection of the small intestine. However, despite the prevalence and burden of this pathology, there are currently no effective treatments for radiotherapy-induced gut toxicity, and this pathology remains unclear. The present study aimed to investigate the changes induced in the rat small intestine after external irradiation of the tongue, and to explore the potential radio-protective effects of melatonin gel. Male Wistar rats were subjected to irradiation of their tongues with an X-Ray YXLON Y.Tu 320-D03 irradiator, receiving a dose o…

Male0301 basic medicineCancer TreatmentDrug Evaluation Preclinicallcsh:MedicineExpressionApoptosisToxicologyPathology and Laboratory Medicinemedicine.disease_causeBiochemistryOxidative Phosphorylation0302 clinical medicineIntestinal mucosaGastrointestinal tractIntestine SmallMedicine and Health SciencesRadiation-injuryIntestinal Mucosalcsh:ScienceEnergy-Producing OrganellesMelatoninCancerMultidisciplinaryNF-kappa BInflammasomeLipid-peroxidationGlutathioneMitochondriaRadiation therapyRadiation Injuries Experimentalmedicine.anatomical_structureOncology030220 oncology & carcinogenesisCancer treatmentToxicityInflammasome activationSmall IntestineExperimental pathologyAnatomyCellular Structures and OrganellesResearch Articlemedicine.drugClinical OncologyMucositismedicine.medical_specialtyRadiation TherapyRadiation-Protective AgentsBioenergeticsBiologyRadiation enteropathyMelatonin03 medical and health sciencesTongueInternal medicineSepsisNLR Family Pyrin Domain-Containing 3 ProteinmedicineAnimalsRats WistarMouthToxicitylcsh:RBiology and Life SciencesCell BiologySmall intestinemedicine.diseaseHormonesSmall intestinePathobiologyGastrointestinal TractOxidative Stress030104 developmental biologyEndocrinologylcsh:QClinical MedicineDigestive SystemGelsOxidative stress
researchProduct

Efficacy of N-acetylcysteine in the prevention of alcohol relapse-like drinking: Study in long-term ethanol-experienced male rats

2021

Alcohol use disorders are chronic and highly relapsing disorders, thus alcoholic patients have a high rate of recidivism for drug use even after long periods of abstinence. The literature points to the potential usefulness of N-acetylcysteine (NAC) in the management of several substance use disorders probably due to its capacity to restore brain homeostasis of the glutamate system disrupted in addiction. However, there is little evidence in the case of alcohol. The aim of this study was to explore the potential anti-relapse efficacy of NAC using the alcohol deprivation effect (ADE) model in long-term experienced rats. Two experiments were performed in male Wistar rats to: (a) test the effic…

Male0301 basic medicineDrugAlcohol DrinkingInjections Subcutaneousmedia_common.quotation_subjectDrug Evaluation PreclinicalAlcoholPharmacologyInfusions Subcutaneous:CIENCIAS DE LA VIDA [UNESCO]ethanol relapse preventionAcetylcysteineRandom Allocation03 medical and health sciencesCellular and Molecular Neurosciencechemistry.chemical_compoundSubcutaneous injection0302 clinical medicinePharmacotherapyalcohol use disordersRecurrenceglutamate neurotransmissionUNESCO::CIENCIAS DE LA VIDAAnimalsMedicineRats Wistarmedia_commonEthanolEthanolbusiness.industryAbstinencealcohol deprivation effecAcetylcysteineRatsSubstance Withdrawal SyndromeAlcoholismRegimen030104 developmental biologychemistryModels Animalbusiness030217 neurology & neurosurgerymedicine.drug
researchProduct

Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma

2018

Abstract Purpose: Nilotinib plus doxorubicin showed to be synergistic regarding apoptosis in several sarcoma cell lines. A phase I/II trial was thus designed to explore the feasibility of nilotinib as coadjuvant of doxorubicin by inhibiting MRP-1/P-gp efflux activity. The phase I part of the study is presented here. Patients and Methods: Nilotinib 400 mg/12 hours was administered in fixed dose from day 1 to 6, and doxorubicin on day 5 of each cycle. Three dose escalation levels for doxorubicin at 60, 65, and 75 mg/m2 were planned. Cycles were repeated every 3 weeks for a total of 4 cycles. Eligible subtypes were retroperitoneal liposarcoma, leiomyosarcoma, and unresectable/metastatic high-g…

Male0301 basic medicineLeiomyosarcomaOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentDrug Evaluation PreclinicalApoptosisLiposarcomaNeutropeniaMice03 medical and health sciences0302 clinical medicineCell Line TumorInternal medicineAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumormedicineAnimalsHumansCell ProliferationNeoplasm StagingChemotherapybusiness.industrySarcomamedicine.diseasePyrimidines030104 developmental biologyOncologyNilotinibChemotherapy AdjuvantDoxorubicin030220 oncology & carcinogenesisFemaleSarcomaNeoplasm GradingChondrosarcomabusinessFebrile neutropeniamedicine.drugClinical Cancer Research
researchProduct

Muricholic Acids Promote Resistance to Hypercholesterolemia in Cholesterol-Fed Mice

2021

International audience; Background and aims: Hypercholesterolemia is a major risk factor for atherosclerosis and cardiovascular diseases. Although resistant to hypercholesterolemia, the mouse is a prominent model in cardiovascular research. To assess the contribution of bile acids to this protective phenotype, we explored the impact of a 2-week-long dietary cholesterol overload on cholesterol and bile acid metabolism in mice. Methods: Bile acid, oxysterol, and cholesterol metabolism and transport were assessed by quantitative real-time PCR, western blotting, GC-MS/MS, or enzymatic assays in the liver, the gut, the kidney, as well as in the feces, the blood, and the urine. Results: Plasma tr…

Male0301 basic medicineMuricholic acidDrug Evaluation PreclinicalReceptors Cytoplasmic and NuclearCholesterol Dietarychemistry.chemical_compound0302 clinical medicineBiology (General)Spectroscopy2. Zero hungerKidney[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyBile acidChemistryGeneral Medicine3. Good healthComputer Science ApplicationsBlotChemistrymedicine.anatomical_structureCholesterolFXR030220 oncology & carcinogenesislipids (amino acids peptides and proteins)LXRmedicine.medical_specialtyOxysterolQH301-705.5medicine.drug_classHypercholesterolemiaArticleCatalysisBile Acids and SaltsInorganic Chemistry03 medical and health sciencesIn vivoInternal medicinemedicine[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular BiologyAnimals[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyPhysical and Theoretical ChemistryLiver X receptorQD1-999Molecular BiologyCholesterolOrganic ChemistryCholic AcidsBile acidsMice Inbred C57BL030104 developmental biologyEndocrinology[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Both cholestatic and steatotic drugs trigger extensive alterations in the mRNA level of biliary transporters in rat hepatocytes: Application to devel…

2016

Disruption of the vectorial bile acid transport in the liver is a key feature of cholestatic drugs, although many causal and mechanistic aspects are still unknown. The aim of the present study was to explore if cholestatic drugs can repress or induce the expression of hepatic transporters. To this end, sandwich-cultured rat hepatocytes were treated with cholestatic and non-cholestatic (steatotic, non-hepatotoxic, etc.) drugs and the mRNA expression of 10 uptake and efflux biliary transporters was measured. Results evidenced that all cholestatic drugs cause extensive alterations in the mRNA expression of most biliary transporters. Surprisingly, nearly all steatotic drugs also affected the ex…

Male0301 basic medicinePathologymedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsDrug Evaluation PreclinicalOrganic Anion Transporters Sodium-IndependentPharmacologyBiologyToxicology030226 pharmacology & pharmacyRats Sprague-Dawley03 medical and health sciences0302 clinical medicineCholestasisPredictive Value of TestsIn vivomedicineAnimalsBileRNA MessengerCells CulturedCholestasisMultidrug resistance-associated protein 2Fatty liverTransporterGeneral Medicinemedicine.diseaseRatsFatty Liver030104 developmental biologyTetracyclinesHepatocytesBiomarker (medicine)EffluxSteatosisCarrier ProteinsBiomarkersToxicology Letters
researchProduct